United
States Prostate Cancer Testing Market is expected to grow at an impressive rate
during the forecast period, 2024-2028. The
major factors include increasing prevalence of prostate cancer in
men, increasing prostate cancer screening and testing, early diagnosis of
prostate cancer and increasing interest of government in cancer testing and
medical advancement. According
to Global Cancer Observatory, in 2020, around 2281,658 new
cancer cases were reported in the United States, among which 209,512 cases
reported were of prostate cancer. Additionally, increasing awareness among public for early
prostate diagnosis and detection is further expected to drive the growth of United
States prostate cancer testing market.
The prostate gland's aberrant
cells multiply and uncontrollably enlarge in men in prostate cancer. The tenth
leading cause of mortality overall and the sixth major cause of death in men is
prostate cancer. According to Statista, the United States leads among
all countries across the globe in terms of spending on research and
development, with expenditure exceeding around USD679.4 billion.
Rising prevalence of prostate cancer
In United States, prostate
cancer is the most prevalent cancer in men. This is diagnosed in about 6 out of
10 men who are 65 years old and rare in men under 40 years. Prostate cancer is the
second most common cancer among American males, after lung cancer. For
instance, in the United States, it was predicted that about 268,490 new cases
of prostate cancer were reported in 2022, up from 192,280 new cases in 2009.
Moreover, it was estimated that in 2022 around 34,500 men would die of prostate
cancer in the U.S.
Growing Geriatric Population
Globally,
the cancer is the leading cause of death. According to American Society of
Clinical Oncologists, prostate cancer is more than twice as likely in people
over 70 years as compared to younger people. This is due to genetic
disorder, unhealthy lifestyle, environment, radiations, physical carcinogens, chemical
carcinogens as well as biological carcinogens. The need to develop testing
procedures for cancer is expected to support the growth of US prostate cancer
testing market.
Government Initiatives related to Prostate Cancer
The
government provides funding for developing new technologies to enhance testing
of prostate cancer positively. For instance, the National Cancer Institute
initiated Prostate Specialized Programs of Research Excellence (SPORE)-a
program designed to convert scientific findings into clinical settings-based
outcomes. The institute also facilitates the development of new technologies
and studies to gain a better understanding of monitoring, prevention,
diagnosis, and treatment. Such initiatives are expected to drive the
growth of United States Prostate Cancer Testing Market.
Technological
Development
The
techniques like prostate-specific antigen (PSA) testing which have developed
over the years that confirm the tumor progression and proliferation have
created new prospects for the growth of prostate cancer testing over the years. Moreover, prostate cancer testing
is essential in precision medicine because it assures the safe and successful
use of testing methods. Additionally, most of the companies in the U.S.
prostate cancer testing market provide biomarker tests that are urine, blood,
and tissue-based, as well as testing services. This, in turn shows an
impressive rate for the growth of the United States prostate cancer market.
Recent Developments
According to the Journal of
the National Cancer Institute, in September 2022, a company namely Veracyte,
Inc. announced the publishing of data to demonstrate that the company’s
decipher prostate genomic classifier may help identify African American men
with early, localized prostate cancer who are most likely to harbor more
aggressive disease.
Additionally, in June 2021, Thermo Fisher
Scientific announced submissions open for the Oncomine Clinical Research Grant
program to support clinical research projects in oncology. Due to this grant,
the funding for high-quality molecular profiling studies focusing on the impact
of immune-based treatments for cancer patients.
Download Free Sample Report
Market Segmentation
United
States Prostate Cancer Testing Market can be segmented by biomarker
type,
application, end user, region and competitive
landscape. Based on biomarker type, the
market can be segmented into pre-biopsy/post-negative biopsy
testing, initial evaluation: prostate-specific antigen (Total PSA, Free PSA), post-biopsy
tissue testing. Based on application, the market can be segmented into diagnostics biomarkers, and prognostics biomarkers.
In terms of end user, the market can be segmented into cancer
research institutes, diagnostic laboratories, hospitals and clinics, ambulatory
surgical center (ASCs), and others.
Market Players
F. Hoffmann-La Roche Ltd (Foundation
Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad
Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent
Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc.
(Fujeribio) etc. are
some of the leading companies operating in the market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022
and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast, company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
Biomarker Type
Application
End User
Region
Company
|
|
Regional scope
|
Northeast Region,
Midwest Region, South Region, West Region
|
|
Key companies profiled
|
F. Hoffmann-La Roche Ltd (Foundation
Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad
Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.),
Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group
Holdings, Inc. (Fujeribio)
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United States
Prostate Cancer Testing Market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
·
United States Prostate Cancer Testing Market, By Biomarker Type
o
Pre-Biopsy/Post-Negative
Biopsy Testing
o
Initial
Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
o
Post-Biopsy
Tissue Testing
·
United
States Prostate Cancer Testing Market, By Application
o
)
o
Diagnostics
Biomarkers
o
Prognostics
Biomarkers
·
United
States Prostate Cancer Testing Market, By End User
o Cancer Research Institutes
o Diagnostic Laboratories
o Hospitals and Clinics
o Ambulatory Surgical Center
(ASCs)
o Others
·
United States Prostate
Cancer Testing Market, By Region:
o
Northeast
o
Midwest
o
South
o
West
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in United States Prostate Cancer Testing Market
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market
players (up to five).
United States Prostate Cancer Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]